Status | Study |
Completed |
Study Name: Intralesional Antimony for Bolivian Cutaneous Leishmaniasis Condition: Leishmaniasis Cutaneous Leishmaniasis Date: 2011-02-17 Interventions: Drug: pentavalent antimony 3 i |
Completed |
Study Name: Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis Condition: Cutaneous Leishmaniasis Date: 2010-01-13 Interventions: Drug: Liposomal meglumine antimoniate (Glucantime) |
Recruiting |
Study Name: Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Condition: Cutaneous Leishmaniasis Date: 2009-02-08 Interventions: Procedure: Photodynamic therapy |
Completed |
Study Name: Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World Condition: Cutaneous Leishmaniasis Date: 2008-06-20 Interventions: Drug: WR 279,396 A topical cre |
Terminated |
Study Name: Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Condition: Cutaneous Leishmaniasis Date: 2008-05-20 Interventions: Drug: Glucantime® 15mg Sb |
Completed |
Study Name: Sodium Stibogluconate Treatment of Leishmaniasis Condition: Leishmaniasis Date: 2008-04-15 Interventions: Drug: Sodium Stibogluconate (SSG) 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with |
Completed |
Study Name: Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Condition: Leishmaniasis Date: 2008-04-08 Interventions: Drug: Sodium Stibogluconate (SSG) 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with |
Completed |
Study Name: An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Condition: Visceral Leishmaniasis Date: 2008-02-20 Interventions: Drug: Paromomycin 11 mg/kg for |
Completed |
Study Name: Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Condition: Cutaneous Leishmaniasis Date: 2008-01-21 Interventions: Drug: WR 279,396 topical cream |
Completed |
Study Name: Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Condition: Visceral Leishmaniasis Date: 2008-01-17 Interventions: Drug: Paromomycin sulfate Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for |